Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma

JCO Precis Oncol. 2021 Nov:5:1160-1165. doi: 10.1200/PO.21.00127.

Angela Mweempwa¹, Huiling Xu^{2

3

4}, Joseph H A Vissers^{5

6}, Richard W Tothill^{5

6}, Andrew D Pattison⁵, Andrew P Fellowes^{2

3}, David M Thomas⁷, Gary Richardson⁸, Rodney J Hicks^{6

9}, Sean M Grimmond⁵, Stephen B Fox^{2

3

4

6}, Stephen J Luen¹, Jayesh Desai^{1

6}, Benjamin J Solomon^{1

6}

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Department of Clinical Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia.
⁵ Centre for Cancer Research and Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.
⁶ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
⁷ The Kinghorn Cancer Centre and Cancer Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
⁸ Cabrini Health, Department of Medical Oncology, Malvern, Victoria, Australia.
⁹ Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

No abstract available

Publication types